Leukemia or blood cancer is the cancer of blood forming tissues: bone marrow and lymphatic system. As the name suggests, it affects the leucocytes or white blood cells. In this type of cancer, the DNA of leucocytes gets damaged as a result of which they grow and divide uncontrollably. These cells keep on growing and start accumulating, thereby preventing the healthy white blood cells from growing and functioning. 

Global leukemia therapeutics market is expected to grow at a formidable rate during the forecast period. The global leukemia therapeutics market is driven by the technological advancements and innovations in the field of blood cancer testing on account of the growing number of patients suffering from leukemia. Additionally, growing awareness among the population pertaining to adoption of preventive healthcare is further expected to propel the market during forecast period. Furthermore, supportive government initiatives & policies for promoting cancer awareness is anticipated to fuel the market growth until 2025. 

The global leukemia therapeutics market can be segmented based on factor, severity, blood cell, age groups, sex, treatment, diagnosis, route of administration, drugs, company and region. Based on severity, the market can be bifurcated into acute and chronic. The chronic leukemia segment is expected to dominate the market during forecast period. This can be accredited to the rising geriatric population and increasing funding for cancer research and the development of new therapies. 

Regionally, the leukemia therapeutics market has been segmented into Asia-Pacific, North America, South America, Europe, and Middle East & Africa. Among these regions, North America is expected to dominate the market during forecast period. This can be attributed to the presence of a large geriatric population base in the country. Additionally, the presence of key players in the region is further expected to propel the market over 2025.   

Major players operating in the global leukemia therapeutics market include Novartis, AbbVie, Bristol-Myers Squibb, Roche, Amgen, Gilead sciences, Celgene, Eisai, AstraZeneca, Incyte Corporation, Johnson & Johnson, Biogen, Merck, PerkinElmer, Eli Lilly, Abbott, Sumitomo Dainippon Pharma, Thermo Fisher Scientific, Otsuka Holdings, Astellas Pharma and others. The companies operating in the market are using organic strategies such as product launches, mergers and collaborations to boost their share. For instance, in August 2017, Bristol-Myers Squibb acquired IFM Therapeutics in order to fortify its oncology product line.

Years considered for this report:

Historical Years: 2015-2018

Base Year: 2019

Estimated Year: 2020

Forecast Period: 2021–2025

Objective of the Study:

  • To analyze and forecast the market size of global leukemia therapeutics market.
  • To classify and forecast global leukemia therapeutics market based on factor, severity, blood cell, age groups, sex, treatment, diagnosis, route of administration, drugs, company and regional distribution.
  • To identify drivers and challenges for global leukemia therapeutics market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in global leukemia therapeutics market.
  • To identify and analyze the profile of leading players operating in global leukemia therapeutics market.


Click here to download the sample

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of manufacturers across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the manufacturers which could not be identified due to the limitations of secondary research. TechSci Research analyzed the manufacturers, distribution channels and presence of all major players across the globe.

TechSci Research calculated the market size of global leukemia therapeutics market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.


Key Target Audience:

  • Leukemia therapeutics manufacturers, suppliers, distributors and other stakeholders
  • Government bodies such as regulating authorities and policy makers
  • Organizations, forums and alliances related to leukemia therapeutics
  • Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as manufacturers, suppliers and partners, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, global leukemia therapeutics market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Market, By Factor:
    • Artificial ionizing radiation
    • Viruses
    • Chemotherapy
    • Genetics
    • Immune suppression
    • Others
  • Market, By Severity:
    • Acute
    • Chronic
  • Market, By Blood Cell:
    • Lymphocytic
    • Myelogenous
  • Market, By Age Groups:
    • 0-15
    • 15-30
    • 30-50
    • 50+
  • Market, By Sex:
    • Male
    • Female
  • Market, By Treatment:
    • Targeted Therapy
    • Interferon Therapy
    • Radiation Therapy
    • Surgery
    • Stem Cell Transplantation
    • Drugs
    • Gene Therapy
    • Immunotherapy
    • Vaccine Therapy
    • Chemotherapy
    • Blood Transfusion
  • Market, By Diagnosis:
    • Blood test
    • Biopsy
    • Physical Exam
    • Imagining
      • CT-SCAN
      • X-RAY
      • MRI
  • Market, By Route of Administration:
    • Oral
    • Intravenous
    • Subcutaneous
    • Intramuscular
    • Intrathecal
  • Market, By Drugs:
    • Antimetabolites
    • Biosimilars
    • Asparagine-Specific Enzymes
    •  Hormones (Corticosteroids)
    • Hypomethylating (Demethylating) Agents
    • Tyrosine Kinase Inhibitors
    • Others
  • Market, By Region:
    • North America
      • United States
      • Canada
      • Mexico
    • Europe
      • Germany
      • France
      • United Kingdom
      • Italy
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Singapore
      • Australia
    • Middle East & Africa
      • South Africa
      • Saudi Arabia
      • UAE
    • South America
      • Brazil
      • Argentina
      • Colombia

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global leukemia therapeutics market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).
It is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at sales@techsciresearch.com  

In case you don’t find what you are looking for, please get in touch with our custom research team at sales@techsciresearch.com

1.    Product Overview

2.    Research Methodology

3.    Executive Summary

4.    Voice of Customer

5.    Global Leukemia Therapeutics Market Outlook

5.1.  Market Size & Forecast

5.1.1.     By Value & Volume

5.2.  Market Share & Forecast

5.2.1.     By Factor (Artificial ionizing radiation, Viruses, Chemotherapy, Genetics, Immune suppression, Others)

5.2.2.     By Severity (Acute, Chronic)

5.2.3.     By Blood Cell (Lymphocytic, Myelogenous)

5.2.4.     By Age Groups (0-15, 15-30, 30-50, 50+)

5.2.5.     By Sex (Male, Female)

5.2.6.     By Treatment (Targeted Therapy, Interferon Therapy, Radiation Therapy, Surgery, Stem Cell Transplantation, Drugs, Gene Therapy, Immunotherapy, Vaccine Therapy, Chemotherapy, Blood Transfusion)

5.2.7.     By Diagnosis (Blood test, Biopsy, Physical Exam, Imagining (CT-SCAN, X-RAY, MRI))

5.2.8.     By Route of Administration (Oral, Intravenous, Subcutaneous, Intramuscular, Intrathecal)

5.2.9.     By Drugs (Antimetabolites, Biosimilars, Asparagine-Specific Enzymes, Hormones (Corticosteroids), Hypomethylating (Demethylating) Agents, Tyrosine Kinase Inhibitors, Others)

5.2.10.  By Company (2019)

5.2.11.  By Region

5.3.  Market Attractiveness Index

6.    Asia-Pacific Leukemia Therapeutics Market Outlook

6.1.  Market Size & Forecast          

6.1.1.     By Value & Volume

6.2.  Market Share & Forecast

6.2.1.     By Factor

6.2.2.     By Severity

6.2.3.     By Blood Cell

6.2.4.     By Age Groups

6.2.5.     By Sex

6.2.6.     By Treatment

6.2.7.     By Diagnosis

6.2.8.     By Route of Administration

6.2.9.     By Drugs

6.2.10.  By Country

6.3.  Market Attractiveness Index

6.4.  Asia-Pacific: Country Analysis

6.4.1.     China Leukemia Therapeutics Market Outlook

6.4.1.1.         Market Size & Forecast

6.4.1.1.1.             By Value

6.4.1.2.         Market Share & Forecast

6.4.1.2.1.             By Factor

6.4.1.2.2.             By Severity

6.4.1.2.3.             By Blood Cell

6.4.1.2.4.             By Age Groups

6.4.1.2.5.             By Sex

6.4.1.2.6.             By Treatment

6.4.1.2.7.             By Diagnosis

6.4.1.2.8.             By Route of Administration

6.4.1.2.9.             By Drugs

6.4.2.     India Leukemia Therapeutics Market Outlook

6.4.2.1.         Market Size & Forecast

6.4.2.1.1.             By Value

6.4.2.2.         Market Share & Forecast

6.4.2.2.1.             By Factor

6.4.2.2.2.             By Severity

6.4.2.2.3.             By Blood Cell

6.4.2.2.4.             By Age Groups

6.4.2.2.5.             By Sex

6.4.2.2.6.             By Treatment

6.4.2.2.7.             By Diagnosis

6.4.2.2.8.             By Route of Administration

6.4.2.2.9.             By Drugs

6.4.3.     Japan Leukemia Therapeutics Market Outlook

6.4.3.1.         Market Size & Forecast

6.4.3.1.1.             By Value

6.4.3.2.         Market Share & Forecast

6.4.3.2.1.             By Factor

6.4.3.2.2.             By Severity

6.4.3.2.3.             By Blood Cell

6.4.3.2.4.             By Age Groups

6.4.3.2.5.             By Sex

6.4.3.2.6.             By Treatment

6.4.3.2.7.             By Diagnosis

6.4.3.2.8.             By Route of Administration

6.4.3.2.9.             By Drugs

6.4.4.     South Korea Leukemia Therapeutics Market Outlook

6.4.4.1.         Market Size & Forecast

6.4.4.1.1.             By Value

6.4.4.2.         Market Share & Forecast

6.4.4.2.1.             By Factor

6.4.4.2.2.             By Severity

6.4.4.2.3.             By Blood Cell

6.4.4.2.4.             By Age Groups

6.4.4.2.5.             By Sex

6.4.4.2.6.             By Treatment

6.4.4.2.7.             By Diagnosis

6.4.4.2.8.             By Route of Administration

6.4.4.2.9.             By Drugs

6.4.5.     Singapore Leukemia Therapeutics Market Outlook

6.4.5.1.         Market Size & Forecast

6.4.5.1.1.             By Value

6.4.5.2.         Market Share & Forecast

6.4.5.2.1.             By Factor

6.4.5.2.2.             By Severity

6.4.5.2.3.             By Blood Cell

6.4.5.2.4.             By Age Groups

6.4.5.2.5.             By Sex

6.4.5.2.6.             By Treatment

6.4.5.2.7.             By Diagnosis

6.4.5.2.8.             By Route of Administration

6.4.5.2.9.             By Drugs

6.4.6.     Australia Leukemia Therapeutics Market Outlook

6.4.6.1.         Market Size & Forecast

6.4.6.1.1.             By Value

6.4.6.2.         Market Share & Forecast

6.4.6.2.1.             By Factor

6.4.6.2.2.             By Severity

6.4.6.2.3.             By Blood Cell

6.4.6.2.4.             By Age Groups

6.4.6.2.5.             By Sex

6.4.6.2.6.             By Treatment

6.4.6.2.7.             By Diagnosis

6.4.6.2.8.             By Route of Administration

6.4.6.2.9.             By Drugs

7.    Europe Leukemia Therapeutics Market Outlook

7.1.  Market Size & Forecast          

7.1.1.     By Value & Volume

7.2.  Market Share & Forecast

7.2.1.     By Factor

7.2.2.     By Severity

7.2.3.     By Blood Cell

7.2.4.     By Age Groups

7.2.5.     By Sex

7.2.6.     By Treatment

7.2.7.     By Diagnosis

7.2.8.     By Route of Administration

7.2.9.     By Drugs

7.2.10.  By Country

7.3.  Market Attractiveness Index

7.4.  Europe: Country Analysis

7.4.1.     France Leukemia Therapeutics Market Outlook

7.4.1.1.         Market Size & Forecast

7.4.1.1.1.             By Value

7.4.1.2.         Market Share & Forecast

7.4.1.2.1.             By Factor

7.4.1.2.2.             By Severity

7.4.1.2.3.             By Blood Cell

7.4.1.2.4.             By Age Groups

7.4.1.2.5.             By Sex

7.4.1.2.6.             By Treatment

7.4.1.2.7.             By Diagnosis

7.4.1.2.8.             By Route of Administration

7.4.1.2.9.             By Drugs

7.4.2.     Germany Leukemia Therapeutics Market Outlook

7.4.2.1.         Market Size & Forecast

7.4.2.1.1.             By Value

7.4.2.2.         Market Share & Forecast

7.4.2.2.1.             By Factor

7.4.2.2.2.             By Severity

7.4.2.2.3.             By Blood Cell

7.4.2.2.4.             By Age Groups

7.4.2.2.5.             By Sex

7.4.2.2.6.             By Treatment

7.4.2.2.7.             By Diagnosis

7.4.2.2.8.             By Route of Administration

7.4.2.2.9.             By Drugs

7.4.3.     United Kingdom Leukemia Therapeutics Market Outlook

7.4.3.1.         Market Size & Forecast

7.4.3.1.1.             By Value

7.4.3.2.         Market Share & Forecast

7.4.3.2.1.             By Factor

7.4.3.2.2.             By Severity

7.4.3.2.3.             By Blood Cell

7.4.3.2.4.             By Age Groups

7.4.3.2.5.             By Sex

7.4.3.2.6.             By Treatment

7.4.3.2.7.             By Diagnosis

7.4.3.2.8.             By Route of Administration

7.4.3.2.9.             By Drugs

7.4.4.     Italy Leukemia Therapeutics Market Outlook

7.4.4.1.         Market Size & Forecast

7.4.4.1.1.             By Value

7.4.4.2.         Market Share & Forecast

7.4.4.2.1.             By Factor

7.4.4.2.2.             By Severity

7.4.4.2.3.             By Blood Cell

7.4.4.2.4.             By Age Groups

7.4.4.2.5.             By Sex

7.4.4.2.6.             By Treatment

7.4.4.2.7.             By Diagnosis

7.4.4.2.8.             By Route of Administration

7.4.4.2.9.             By Drugs

8.    North America Leukemia Therapeutics Market Outlook

8.1.  Market Size & Forecast          

8.1.1.     By Value & Volume

8.2.  Market Share & Forecast

8.2.1.     By Factor

8.2.2.     By Severity

8.2.3.     By Blood Cell

8.2.4.     By Age Groups

8.2.5.     By Sex